It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Activation of fibroblasts is essential for physiological tissue repair. Uncontrolled activation of fibroblasts, however, may lead to tissue fibrosis with organ dysfunction. Although several pathways capable of promoting fibroblast activation and tissue repair have been identified, their interplay in the context of chronic fibrotic diseases remains incompletely understood. Here, we provide evidence that transforming growth factor-β (TGFβ) activates autophagy by an epigenetic mechanism to amplify its profibrotic effects. TGFβ induces autophagy in fibrotic diseases by SMAD3-dependent downregulation of the H4K16 histone acetyltransferase MYST1, which regulates the expression of core components of the autophagy machinery such as ATG7 and BECLIN1. Activation of autophagy in fibroblasts promotes collagen release and is both, sufficient and required, to induce tissue fibrosis. Forced expression of MYST1 abrogates the stimulatory effects of TGFβ on autophagy and re-establishes the epigenetic control of autophagy in fibrotic conditions. Interference with the aberrant activation of autophagy inhibits TGFβ-induced fibroblast activation and ameliorates experimental dermal and pulmonary fibrosis. These findings link uncontrolled TGFβ signaling to aberrant autophagy and deregulated epigenetics in fibrotic diseases and may contribute to the development of therapeutic interventions in fibrotic diseases.
Uncontrolled activation of fibroblasts contributes to tissue fibrosis and organ dysfunction. Here the authors demonstrate that the epigenetic control of autophagy is disturbed by a TGFβ-dependent downregulation of MYST1 in systemic sclerosis patients. Restoration of the epigenetic control of autophagy reduces fibroblast activation and ameliorates fibrotic tissue remodeling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Deutsches Zentrum für Immuntherapie, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)
2 Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Deutsches Zentrum für Immuntherapie, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); National Taiwan University, Graduate Institute of Anatomy and Cell Biology, College of Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241)
3 University of Cologne, Faculty of Medicine, Center for Biochemistry, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
4 National Taiwan University, Graduate Institute of Anatomy and Cell Biology, College of Medicine, Taipei, Taiwan (GRID:grid.19188.39) (ISNI:0000 0004 0546 0241)
5 Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Deutsches Zentrum für Immuntherapie, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Central South University, Department of Rheumatology, Xiangya Hospital, Changsha, China (GRID:grid.216417.7) (ISNI:0000 0001 0379 7164)
6 University of Cologne, Faculty of Medicine, Translational Matrix Biology, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777); Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany (GRID:grid.452408.f)